ArticleAnatomical record (Hoboken, N.J. : 2007)2025
Distribution and morphology of serotonin transporter-immunoreactive type I cells in the rat carotid body.
Article in Anatomical record (Hoboken, N.J. : 2007), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Distribution and morphology of serotonin transporter-immunoreactive type I cells in the rat carotid body.Anatomical record (Hoboken, N.J. : 2007) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The present study reexamined the immunolocalization of membranous serotonin transporter (SERT) in the rat carotid body, and demonstrated SERT-immunoreactive cells of unreported morphology. SERT was immunohistochemically localized in a very small population of cell clusters or single type I cells (2.8%) immunoreactive for synaptophysin, the marker of these cells. Intense SERT immunoreactivity outlined the perinuclear cytoplasm and multiple cytoplasmic processes of type I cells. Of SERT-immunoreactive type I cells, 14.6% and 32.6% were immunoreactive for tyrosine hydroxylase (TH) and dopamine beta-hydroxylase, respectively, while 75.9% were immunoreactive for serotonin (5-HT). 5-HT-immunoreactive products were localized in cell bodies rather than cytoplasmic processes. SERT-immunoreactive type I cells were composed of an oval cell body with multiple threads and spherical or elongated cytoplasmic processes. Clusters or single SERT-immunoreactive type I cells were localized between or attached to other TH-immunoreactive type I cells by cell bodies or variform cytoplasmic processes. SERT-immunoreactive type I cells mainly contained bassoon-immunoreactive products in their cell bodies rather than their variform cytoplasmic processes. These results demonstrated the characteristic morphology of SERT-immunoreactive type I cells, which extend multiple cytoplasmic processes with variform terminal parts. Their morphology might be suitable for uptake of 5-HT to control the serotonergic modulation in the carotid body.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.